The subject of space charge due to positive ions slowly moving in parallel plate ionization chambers is considered. A model for the degradation of the detector response is developed, with particular ...emphasis on electromagnetic calorimeters.The topics discussed include: (a) the stationary; (b) the time dependent cases; (c) the limit of very large space charge; (d) the electric field dependence of the electron drift velocity; (e) the effect of longitudinal development of showers; (f) the behaviour of the average reductions of response; (g) the non-uniformity of response for different positions of the shower axis inside the cell defined by the electrodes. The NA48 calorimeter is used as application and for comparison of results.
Both induction chemotherapy and concurrent low-dose cisplatin have been shown to improve results of thoracic irradiation in the treatment of locally advanced non-small-cell lung cancer (NSCLC). This ...phase II study was designed to investigate activity and feasibility of a novel chemoradiation regimen consisting of induction chemotherapy followed by standard radiotherapy and concurrent daily low-dose cisplatin. Previously untreated patients with histologically/cytologically proven unresectable stage IIIA/B NSCLC were eligible. Induction chemotherapy consisted of vinblastine 5 mg m(-2) intravenously (i.v.) on days 1, 8, 15, 22 and 29, and cisplatin 100 mg m(-2) i.v. on days 1 and 22 followed by continuous radiotherapy (60 Gy in 30 fractions) given concurrently with daily cisplatin at a dose of 5 mg m(-2) i.v. Thirty-two patients were enrolled. Major toxicity during induction chemotherapy was haematological: grade III-IV leukopenia was observed in 31% and grade II anaemia in 16% of the patients. The most common severe toxicity during concurrent chemoradiation consisted of grade III leukopenia (21% of the patients); grade III oesophagitis occurred in only two patients and pulmonary toxicity in one patient who died of this complication. Eighteen of 32 patients (56%, 95% CI 38-73%) had a major response (11 partial response, seven complete response). With a median follow-up of 38.4 months, the median survival was 12.5 months and the actuarial survival rates at 1, 2 and 3 years were 52%, 26% and 19% respectively. The median event-free survival was 8.3 months with a probability of 40%, 23% and 20% at 1, 2 and 3 years respectively. Induction chemotherapy followed by concurrent daily low-dose cisplatin and thoracic irradiation, in patients with locally advanced NSCLC, is active and feasible with minimal non-haematological toxicity. Long-term survival results are promising and appear to be similar to those of more toxic chemoradiation regimens, warranting further testing of this novel chemoradiation strategy.
A measurement of the form factors of charged kaon semileptonic decays is presented, based on 4.4 × 106K± → π0e±νe (K e3 ± ) and 2.3 × 106K± → π0μ±νμ (K μ3 ±) decays collected in 2004 by the NA48/2 ...experiment. The results are obtained with improved precision as compared to earlier measurements. The combination of measurements in the K e3 ± and K μ3 ± modes is also presented.
Abstract The NA48/2 experiment at CERN reports the first observation of the K ± → π 0 π 0 μ ± ν decay based on a sample of 2437 candidates with 15% background contamination collected in 2003–2004. ...The decay branching ratio in the kinematic region of the squared dilepton mass above 0.03 GeV2/c 4 is measured to be (0.65 ± 0.03) × 10 −6. The extrapolation to the full kinematic space, using a specific model, is found to be (3.45 ± 0.16) × 10 −6, in agreement with chiral perturbation theory predictions.
The NA62 experiment recorded a large sample of K+→μ+νμ decays in 2007. A peak search has been performed in the reconstructed missing mass spectrum. In the absence of a signal, limits in the range ...2×10−6 to 10−5 have been set on the squared mixing matrix element |Uμ4|2 between muon and heavy neutrino states, for heavy neutrino masses in the range 300–375 MeV/c2. The result extends the range of masses for which upper limits have been set on the value of |Uμ4|2 in previous production search experiments.
Reduction in the mean glycemic index (GI) of diets of 12 hyperlipidemic patients from 82 +/- 1 to 69 +/- 2 units (p less than 0.001) for a 1 mo period resulted in a significant reduction in total and ...LDL serum cholesterol and serum triglyceride by comparison with the mean lipid values for the preceding and following control months. The change in GI of the diet was achieved largely through manipulation of the cereal products and was not related to large differences in the amount of dietary fiber. In addition, apart from a small mean increase in unsaturated fat and calorie intake during the control periods, no difference was seen between the proportion of macronutrients on either treatment as determined by 1 wk diet histories recorded on alternate weeks throughout the 3 mo study. Selection of low glycemic index foods may therefore be a useful adjunct to the management of hyperlipidemia.
The NA62 experiment at CERN collected a large sample of charged kaon decays with a highly efficient trigger for decays into electrons in 2007. The kaon beam represents a source of tagged neutral pion ...decays in vacuum. A measurement of the electromagnetic transition form factor slope of the neutral pion in the time-like region from ∼1 million fully reconstructed π0 Dalitz decay is presented. The limits on dark photon production in π0 decays from the earlier kaon experiment at CERN, NA48/2, are also reported.
The antiemetic efficacy of ondansetron and dexamethasone (Ondex) was randomly compared to that of high-dose metoclopramide, dexamethasone, and orphenadrine (Control) in the prevention of emesis ...induced by cyclophosphamide-doxorubicin chemotherapy in 64 chemotherapy-naive breast cancer patients. For the control of acute emesis (day 1), patients were randomized to receive either ondasetron 8 mg p.o. 1 hour prior to chemotherapy (CT) and repeated after 6 and 12 hours plus dexamethasone 20 mg i.v. 40 minutes prior to CT (Ondex) or dexamethasone 20 mg i.v. 40 minutes prior to CT, orphenadrine 40 mg i.m. 35 minutes prior to CT and metoclopramide 3 mg/kg i.v. 30 minutes prior to CT and repeated after 90 minutes followed by 40 mg p.o. every 3 hours for 4 times (Control). To control delayed emesis, patients on Ondex received ondansetron 8 mg PO t.i.d. days 2 and 3 and patients in the Control arm received metoclopramide 0.5 mg/kg p.o. q.i.d. and dexamethasone 8 mg i.m. b.i.d. days 2 and 3. Complete and major control of acute emesis was observed in 74%/94% and 44%/67% of patients treated with Ondex and Control, respectively (p < .01/p < .005). Acute nausea was absent in 38% and 34% of patients treated with Ondex and Control, respectively (p = NS). Complete and major control of delayed emesis (days 2-5) was observed in 65%/91% versus 44%/66% of patients in the Ondex and Control arms, respectively (p = NS/p < .01). In patients receiving 6 courses of FEC/FAC, control of acute emesis was significantly superior with Ondex at all treatment courses.
PDF
